196 related articles for article (PubMed ID: 33339518)
1. Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.
Freytag M; Kluth M; Bady E; Hube-Magg C; Makrypidi-Fraune G; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Wittmer C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Luebke AM; Simon R; Sauter G; Schlomm T; Möller K
BMC Cancer; 2020 Dec; 20(1):1220. PubMed ID: 33339518
[TBL] [Abstract][Full Text] [Related]
2. Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.
Ishii H; Saitoh M; Sakamoto K; Kondo T; Katoh R; Tanaka S; Motizuki M; Masuyama K; Miyazawa K
J Biol Chem; 2014 Oct; 289(40):27386-99. PubMed ID: 25143390
[TBL] [Abstract][Full Text] [Related]
3. Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization.
Zhao Y; Li M; Wu W; Miao W; Liu H
Front Immunol; 2023; 14():1161273. PubMed ID: 37090731
[TBL] [Abstract][Full Text] [Related]
4. Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer.
Deloria AJ; Höflmayer D; Kienzl P; Łopatecka J; Sampl S; Klimpfinger M; Braunschmid T; Bastian F; Lu L; Marian B; Stättner S; Holzmann K
Oncotarget; 2016 Nov; 7(45):73800-73816. PubMed ID: 27650542
[TBL] [Abstract][Full Text] [Related]
5. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
[No Abstract] [Full Text] [Related]
7. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
8. Epithelial Splicing Regulatory Protein 1 Is Overexpressed in Breast Cancer and Predicts Poor Prognosis for Breast Cancer Patients.
Liu X; Wang Q; Song S; Feng M; Wang X; Li L; Liu Y; Shi C
Med Sci Monit; 2021 Jul; 27():e931102. PubMed ID: 34262011
[TBL] [Abstract][Full Text] [Related]
9. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
10. A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.
Elhasnaoui J; Ferrero G; Miano V; Franchitti L; Tarulli I; Coscujuela Tarrero L; Cutrupi S; De Bortoli M
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887187
[TBL] [Abstract][Full Text] [Related]
11. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events.
Warzecha CC; Shen S; Xing Y; Carstens RP
RNA Biol; 2009; 6(5):546-62. PubMed ID: 19829082
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.
Fici P; Gallerani G; Morel AP; Mercatali L; Ibrahim T; Scarpi E; Amadori D; Puisieux A; Rigaud M; Fabbri F
Oncotarget; 2017 Jan; 8(2):2423-2436. PubMed ID: 27911856
[TBL] [Abstract][Full Text] [Related]
13. Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression.
Hayakawa A; Saitoh M; Miyazawa K
Adv Exp Med Biol; 2017; 925():33-40. PubMed ID: 27401076
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer.
Stinnesbeck M; Kristiansen A; Ellinger J; Hauser S; Egevad L; Tolkach Y; Kristiansen G
APMIS; 2021 Apr; 129(4):204-212. PubMed ID: 33455017
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
17. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
Luebke AM; Ricken W; Kluth M; Hube-Magg C; Schroeder C; Büscheck F; Möller K; Dum D; Höflmayer D; Weidemann S; Fraune C; Hinsch A; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Minner S; Simon R; Sauter G; Wilczak W; Meiners J
Int J Cancer; 2020 Jul; 147(2):575-583. PubMed ID: 32150281
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
Melling N; Taskin B; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Heinzer H; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Schlomm T; Krech T
Prostate; 2016 Feb; 76(3):259-72. PubMed ID: 26764246
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
